Literature DB >> 21825840

Increased right ventricular glucose metabolism in patients with pulmonary arterial hypertension.

Mehmet Mustafa Can1, Cihangir Kaymaz, Ibrahim Halil Tanboga, Hacer Ceren Tokgoz, Nesrin Canpolat, Erdem Turkyilmaz, Kenan Sonmez, Nihal Ozdemir.   

Abstract

BACKGROUND AND AIMS: We aimed to assess the characteristics of glucose utilization in left and right ventricle (LV, RV) myocardium with F-18 fluorodeoxyglucose (FDG) on positron emission tomography in patients with pulmonary arterial hypertension (PAH), and to evaluate whether predominance of RV glucose metabolism as compared with that in LV relates to clinical, hemodynamic, echocardiographic, and neurohormonal parameters.
METHODS: The study group comprised 23 patients with PAH and 16 healthy controls who underwent FDG positron emission tomography. The ratio of RV uptake (u) of FDG to those of LV was used as a marker for the glucose utilization by RV myocardium. Six-minute walking distance, plasma brain natriuretic peptide (BNP), planimetric echo measures of RV and LV areas, pulmonary arterial systolic pressure estimated by Doppler, Tei index, tricuspid annular excursion, and systolic tissue velocity (St) were used to assess the RV function.
RESULTS: The patients with PAH had significantly higher FDG SUV ratios as compared with controls. The RV to LV FDGu ratio showed a high correlation with PAPs (r=0.87, P<0.05), BNP (r=0.63, P<0.05), and planimetric echo measures of RV to LV area ratio (r=0.61, P<0.05); a mild correlation with Tei index (r=0.47, P<0.05); and a high and inverse correlation with tricuspid annular excursion (r=-0.80, P<0.05), 6-minute walking distance (r=-0.74, P<0.05), and St (r=-0.68, P<0.05).
CONCLUSIONS: Increased RV myocardium FDG accumulation indicates increased RV loading that correlates with prognostic markers in pulmonary hypertension including reduced exercise capacity, elevated BNP, and echo variables of tricuspid annular function. Moreover, identification of increased RV FDG accumulation predicts the presence but not the severity of elevated pulmonary systolic pressure.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21825840     DOI: 10.1097/RLU.0b013e3182177389

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  31 in total

Review 1.  Pathobiology of pulmonary arterial hypertension and right ventricular failure.

Authors:  Norbert F Voelkel; Jose Gomez-Arroyo; Antonio Abbate; Harm J Bogaard; Mark R Nicolls
Journal:  Eur Respir J       Date:  2012-06-27       Impact factor: 16.671

2.  Pulmonary arterial hypertension treatment with carvedilol for heart failure: a randomized controlled trial.

Authors:  Samar Farha; Didem Saygin; Margaret M Park; Hoi I Cheong; Kewal Asosingh; Suzy Aa Comhair; Olivia R Stephens; Emir C Roach; Jacqueline Sharp; Kristin B Highland; Frank P DiFilippo; Donald R Neumann; W H Wilson Tang; Serpil C Erzurum
Journal:  JCI Insight       Date:  2017-08-17

Review 3.  Update on novel targets and potential treatment avenues in pulmonary hypertension.

Authors:  John C Huetsch; Karthik Suresh; Meghan Bernier; Larissa A Shimoda
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-09-02       Impact factor: 5.464

4.  Assessment of right ventricular metabolism: An emerging tool for monitoring pulmonary artery hypertension.

Authors:  Attila Feher; Albert J Sinusas
Journal:  J Nucl Cardiol       Date:  2016-11-18       Impact factor: 5.952

5.  Hypoxia-induced glucose-6-phosphate dehydrogenase overexpression and -activation in pulmonary artery smooth muscle cells: implication in pulmonary hypertension.

Authors:  Sukrutha Chettimada; Rakhee Gupte; Dhwajbahadur Rawat; Sarah A Gebb; Ivan F McMurtry; Sachin A Gupte
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-12-05       Impact factor: 5.464

Review 6.  Novel therapeutic approaches to preserve the right ventricle.

Authors:  Samar Farha; Erika L Lundgrin; Serpil C Erzurum
Journal:  Curr Heart Fail Rep       Date:  2013-03

7.  Evaluation of right ventricular volume and ejection fraction by gated (18)F-FDG PET in patients with pulmonary hypertension: comparison with cardiac MRI and CT.

Authors:  Lei Wang; Yan Zhang; Chaowu Yan; Jianguo He; Changming Xiong; Shihua Zhao; Wei Fang
Journal:  J Nucl Cardiol       Date:  2013-01-26       Impact factor: 5.952

Review 8.  Metabolism of the right ventricle and the response to hypertrophy and failure.

Authors:  S Elissa Altin; P Christian Schulze
Journal:  Prog Cardiovasc Dis       Date:  2012 Sep-Oct       Impact factor: 8.194

Review 9.  State of the art: advanced imaging of the right ventricle and pulmonary circulation in humans (2013 Grover Conference series).

Authors:  Mariëlle C van de Veerdonk; J Tim Marcus; Harm-Jan Bogaard; Anton Vonk Noordegraaf
Journal:  Pulm Circ       Date:  2014-06       Impact factor: 3.017

10.  Fasting 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography to detect metabolic changes in pulmonary arterial hypertension hearts over 1 year.

Authors:  Erika L Lundgrin; Margaret M Park; Jacqueline Sharp; W H Wilson Tang; James D Thomas; Kewal Asosingh; Suzy A Comhair; Frank P DiFilippo; Donald R Neumann; Laura Davis; Brian B Graham; Rubin M Tuder; Iva Dostanic; Serpil C Erzurum
Journal:  Ann Am Thorac Soc       Date:  2013-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.